Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
Background and aimsAlthough COVID-19 vaccination is recommended for the patients with chronic liver disease, the clinical outcomes of COVID-19 vaccinated in patients with chronic hepatitis B (CHB) has not been well characterized. The study aimed to explore the safety and specific antibody responses...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1078666/full |
| _version_ | 1811169404266741760 |
|---|---|
| author | Shiheng Wu Xiaolin Wang Mingyang Feng Xiaoman Liu Xinxing Fan Xiangui Ran Baogui Wang Hui Wang |
| author_facet | Shiheng Wu Xiaolin Wang Mingyang Feng Xiaoman Liu Xinxing Fan Xiangui Ran Baogui Wang Hui Wang |
| author_sort | Shiheng Wu |
| collection | DOAJ |
| description | Background and aimsAlthough COVID-19 vaccination is recommended for the patients with chronic liver disease, the clinical outcomes of COVID-19 vaccinated in patients with chronic hepatitis B (CHB) has not been well characterized. The study aimed to explore the safety and specific antibody responses following COVID-19 vaccination among CHB patients.MethodsPatients with CHB were included. All patients were vaccinated with two doses of inactivated vaccine (CoronaVac) or three doses of adjuvanted protein subunit vaccine (ZF2001). The adverse events were recorded and neutralizing antibody (NAb) were determined 14 days following the whole-course vaccination.ResultsA total of 200 patients with CHB were included. Specific NAb against SARS-CoV-2 were positive in 170 (84.6%) patients. The median (IQR) concentrations of NAb were 16.32 (8.44–34.10) AU/ml. Comparison of immune responses between CoronaVac and ZF2001 vaccines showed no significant differences in neither the concentrations of NAb nor the seropositive rates (84.4 vs. 85.7%). Moreover, we observed lower immunogenicity in older patients and in patients with cirrhosis or underlying comorbidities. The incidences of adverse events were 37 (18.5%) with the most common adverse event as injection side pain [25 (12.5%)], followed by fatigue [15 (7.5%)]. There were no differences in the frequencies of adverse between CoronaVac and ZF2001 (19.3% vs. 17.6%). Almost all of the adverse reactions were mild and self-resolved within a few days after vaccination. Severe adverse events were not observed.ConclusionsCOVID-19 vaccines, CoronaVac and ZF2001 had a favorable safety profile and induced efficient immune response in patients with CHB. |
| first_indexed | 2024-04-10T16:41:47Z |
| format | Article |
| id | doaj.art-0cfacfec6b85448bbabe85f0b2aaad8a |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-10T16:41:47Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-0cfacfec6b85448bbabe85f0b2aaad8a2023-02-08T05:34:00ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-02-011010.3389/fmed.2023.10786661078666Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patientsShiheng Wu0Xiaolin Wang1Mingyang Feng2Xiaoman Liu3Xinxing Fan4Xiangui Ran5Baogui Wang6Hui Wang7Department of Infectious Diseases, Fuyang People's Hospital, Fuyang, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Fuyang People's Hospital, Fuyang, ChinaDepartment of Infectious Diseases, Fuyang People's Hospital, Fuyang, ChinaDepartment of Respiratory and Critical Care Medicine, Fuyang People's Hospital, Fuyang, ChinaDepartment of Infectious Diseases, Fuyang People's Hospital, Fuyang, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBackground and aimsAlthough COVID-19 vaccination is recommended for the patients with chronic liver disease, the clinical outcomes of COVID-19 vaccinated in patients with chronic hepatitis B (CHB) has not been well characterized. The study aimed to explore the safety and specific antibody responses following COVID-19 vaccination among CHB patients.MethodsPatients with CHB were included. All patients were vaccinated with two doses of inactivated vaccine (CoronaVac) or three doses of adjuvanted protein subunit vaccine (ZF2001). The adverse events were recorded and neutralizing antibody (NAb) were determined 14 days following the whole-course vaccination.ResultsA total of 200 patients with CHB were included. Specific NAb against SARS-CoV-2 were positive in 170 (84.6%) patients. The median (IQR) concentrations of NAb were 16.32 (8.44–34.10) AU/ml. Comparison of immune responses between CoronaVac and ZF2001 vaccines showed no significant differences in neither the concentrations of NAb nor the seropositive rates (84.4 vs. 85.7%). Moreover, we observed lower immunogenicity in older patients and in patients with cirrhosis or underlying comorbidities. The incidences of adverse events were 37 (18.5%) with the most common adverse event as injection side pain [25 (12.5%)], followed by fatigue [15 (7.5%)]. There were no differences in the frequencies of adverse between CoronaVac and ZF2001 (19.3% vs. 17.6%). Almost all of the adverse reactions were mild and self-resolved within a few days after vaccination. Severe adverse events were not observed.ConclusionsCOVID-19 vaccines, CoronaVac and ZF2001 had a favorable safety profile and induced efficient immune response in patients with CHB.https://www.frontiersin.org/articles/10.3389/fmed.2023.1078666/fullCOVID-19 vaccineCHB patientssafetyimmunogenicityZF2001CoronaVac |
| spellingShingle | Shiheng Wu Xiaolin Wang Mingyang Feng Xiaoman Liu Xinxing Fan Xiangui Ran Baogui Wang Hui Wang Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients Frontiers in Medicine COVID-19 vaccine CHB patients safety immunogenicity ZF2001 CoronaVac |
| title | Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients |
| title_full | Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients |
| title_fullStr | Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients |
| title_full_unstemmed | Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients |
| title_short | Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients |
| title_sort | safety and immunogenicity of inactivated covid 19 vaccine coronavac and the rbd dimer based covid 19 vaccine zf2001 in chronic hepatitis b patients |
| topic | COVID-19 vaccine CHB patients safety immunogenicity ZF2001 CoronaVac |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1078666/full |
| work_keys_str_mv | AT shihengwu safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients AT xiaolinwang safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients AT mingyangfeng safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients AT xiaomanliu safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients AT xinxingfan safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients AT xianguiran safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients AT baoguiwang safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients AT huiwang safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients |